AAV Vector Manufacturing: Transfection Matters

Recombinant adeno-associated viral (AAV) vector production, like that of many other gene therapy vectors, requires co-transfection of three plasmids into host cells which express and assemble the recombinant viral particles containing the therapeutic gene. However, at large scale, transfection efficiency and viral vector yields are often significantly reduced. Therefore, optimizing the transfection process and its efficiency is paramount to boosting vector titers during scale-up and manufacturing of AAV vectors with new generation transfection reagent addressing large scale manufacturing constraints. In this paper we review Polyplus-transfection’s latest reagent, FectoVIR®-AAV, that has been developed with this in mind to facilitate AAV vector manufacturing process flexibility, scalability and route to market.